Orgametril (Lynestrenol)

Lynestrenol, the active ingredient in Orgametril, is a synthetic progestogen presented as a tablet for oral administration. It is employed in hormonal contraception and for the management of menstrual disorders, providing pregnancy prevention and cycle regulation for women of reproductive age.

GNH USA supplies Orgametril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable global distribution. The product complies with EU pharmaceutical standards and is available for export to multiple regions, and can be integrated into national health programs.

Orgametril (lynestrenol) is a progestogen used in hormonal contraception and menstrual disorder management. - Oral contraception: prevents ovulation and creates endometrial changes to inhibit implantation. - Dysmenorrhea: reduces menstrual pain by stabilizing the endometrial lining. - Irregular menstrual cycles: helps regulate cycle length and flow.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: jaundice or abnormal liver enzymes.

Before initiating therapy, consider the following precautions: - Thrombotic risk assessment: evaluate personal or family history of clotting disorders. - Liver function monitoring: avoid use in patients with active hepatic disease. - Blood pressure check: monitor for hypertension during treatment. - Smoking counseling: advise cessation, especially in women over 35. - Pregnancy avoidance: ensure effective contraception; do not start if pregnancy is suspected. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Concurrent hormonal contraceptives: may increase risk of hormonal excess. - Strong enzyme inducers (e.g., rifampicin, carbamazepine): can markedly reduce efficacy. - Antiepileptic drugs (e.g., phenytoin, phenobarbital): may lower plasma levels.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase drug exposure. - Certain antiretrovirals (e.g., protease inhibitors): may alter metabolism and require monitoring.